Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14539450 | 0.88 | FDPS (0.53) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL4290266 | 0.87 | FDPS (0.63) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL30834676 | 0.87 | FDPS (0.63) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL5448983 | 0.84 | FDPS (0.46) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL30270469 | 0.83 | ALDH1A1 (0.50) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL13220903 | 0.83 | FDPS (0.77) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL28801573 | 0.83 | FDPS (0.50) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL4278039 | 0.83 | ALDH1A1 (0.57) | FDPSESR1ALDH1A1MAPTHPGD | |
| SCHEMBL26213507 | 0.83 | ALDH1A1 (0.50) | FDPSALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL5447154 | 0.82 | FDPS (0.56) | FDPSALDH1A1MAPTHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022008475-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2022-01-13 | — | — | WO | disclosed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| CN-1812782-A | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors | ACTELION PHARMACEUTICALS LTD (CH) | 2006-08-02 | — | — | CN | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005002574-A1 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-01-13 | — | — | WO | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | FDPS 1728/4885ESR1 3485/4885ALDH1A1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.